Maturitas
Volume 55, Issue 4 , Pages 297-307 , 20 November 2006

Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism

  • Santiago Palacios

      Affiliations

    • Instituto Palacios, Salud y Medicina de la Mujer, Madrid, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34 91 578 20 05; fax: +34 91 431 99 51.
    • ,
  • Jean-Michel Foidart

      Affiliations

    • Department of Obstetrics, Gynecology and Senology at the University of Liege, Belgium
    • ,
  • Andrea R. Genazzani

      Affiliations

    • Department of Obstetrics and Gynecology, University of Pisa, Italy

Received 19 July 2006 ,Accepted 22 July 2006.

References 

  1. Hill K. The demography of menopause. Maturitas. 1996;23:113–127
  2. Consensus conference on hormone replacement therapy, October 2003. Final consensus statement. Royal College of Physicians of Edinburgh. Available at http://www.rcpe.ac.uk/education/standards/consensus/hrt_03.php [Accessed 6 July 2006].
  3. Sturdee DW, Barlow DH, Ulrich LG, et al. Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen-progestagen replacement therapy? UK Continuous Combined HRT Study Investigators. Lancet. 1994;344:979–982
  4. Gambrell RD, Massey FM, Castaneda TA, et al. Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol. 1980;55:732–738
  5. Position Statement by the Executive Committee of the International Menopause Society. Guidelines for hormone treatment of women in the menopausal transition and beyond. Maturitas. 2005;51:15–20
  6. National Institutes of Health. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann Intern Med. 2005;142:1003–1013
  7. Skouby SO, Al-Azzawi F, Barlow D, et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas. 2005;51:8–14
  8. North American Menopause Society. Recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 position statement of The North American Menopause Society. Menopause. 2004;11:589–600
  9. Royal College of Obstetricians and Gynaecologists. Menopause and Hormone Replacement—study group recommendation. Consensus views arising from the 47th Study Group: Menopause and Hormone Replacement. Available at http://www.rcog.org.uk/index.asp?PageID=310 [Accessed 6 July 2006].
  10. Staessen J, Bulpitt CJ, Fagard R, et al. The influence of menopause on blood pressure. J Hum Hypertens. 1989;3:427–433
  11. Rosenthal T, Oparil S. Hypertension in women. J Hum Hypertens. 2000;14:691–704
  12. Wassertheil-Smoller S, Anderson G, Psaty BM, et al. Hypertension and its treatment in postmenopausal women: baseline data from the Women's Health Initiative. Hypertension. 2000;36:780–789
  13. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252
  14. Ichikawa J, Sumino H, Ichikawa S, Ozaki M. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women. Am J Hypertens. 2006;19:744–749
  15. Karalis I, Beevers G, Beevers M, Lip GYH. Hormone replacement therapy and arterial blood pressure in postmenopausal women with hypertension. Blood Press. 2005;14:38–44
  16. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523–534
  17. Scuteri A, Bos AJ, Brant LJ, et al. Hormone replacement therapy and longitudinal changes in blood pressure in postmenopausal women. Ann Intern Med. 2001;135:229–238
  18. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273:199–208
  19. Oelkers WK. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids. 1996;61:166–171
  20. Simkin-Silverman LR, Wing RR. Weight gain during menopause. Is it inevitable or can it be prevented?. Postgrad Med. 2000;108:47–56
  21. Van Seumeren I. Weight gain and hormone replacement therapy: are women's fears justified?. Maturitas. 2000;34(Suppl. 1):S3–S8
  22. Strothmann A, Schneider HP. Hormone therapy: the European women's perspective. Climacteric. 2003;6:337–346
  23. Lip GY, Beevers M, Churchill D, Beevers DG. Hormone replacement therapy and blood pressure in hypertensive women. J Hum Hypertens. 1994;8:491–494
  24. Aloia JF, Vaswani A, Russo L, Sheehan M, Flaster E. The influence of menopause and hormonal replacement therapy on body cell mass and body fat mass. Am J Obstet Gynecol. 1995;172:896–900
  25. Arabi A, Garnero P, Porcher R, Pelissier C, Benhamou CL, Roux C. Changes in body composition during post-menopausal hormone therapy: a 2 year prospective study. Hum Reprod. 2003;18:1747–1752
  26. Norman RJ, Flight IH, Rees MC. Oestrogen and progestogen hormone replacement therapy for perimenopausal and postmenopausal women: weight and body fat distribution.. Cochrane Database Syst Rev. 2000;2:CD001018
  27. Utian WH, Gass ML, Pickar JH. Body mass index does not influence response to treatment, nor does body weight change with lower doses of conjugated estrogens and medroxyprogesterone acetate in early postmenopausal women. Menopause. 2004;11:306–314
  28. Gambacciani M, Ciaponi M, Cappagli B, Genazzani AR. Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women. Am J Obstet Gynecol. 2001;185:1180–1185
  29. Sorensen MB, Rosenfalck AM, Hojgaard L, Ottesen B. Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy. Obes Res. 2001;9:622–626
  30. Perrone G, Liu Y, Capri O, et al. Evaluation of the body composition and fat distribution in long-term users of hormone replacement therapy. Gynecol Obstet Invest. 1999;48:52–55
  31. Kritz-Silverstein D, Barrett-Connor E. Long-term postmenopausal hormone use, obesity, and fat distribution in older women. JAMA. 1996;275:46–49
  32. Espeland MA, Stefanick ML, Kritz-Silverstein D, et al. Effect of postmenopausal hormone therapy on body weight and waist and hip girths. Postmenopausal Estrogen–Progestin Interventions Study Investigators. J Clin Endocrinol Metab. 1997;82:1549–1556
  33. Bakken K, Eggen AE, Lund E. Side-effects of hormone replacement therapy and influence on pattern of use among women aged 45–64 years. The Norwegian Women and Cancer (NOWAC) study. Acta Obstet Gynecol Scand. 2004;83:850–856
  34. Reynolds RF, Obermeyer CM, Walker AM, Guilbert D. The role of treatment intentions and concerns about side effects in women's decision to discontinue postmenopausal hormone therapy. Maturitas. 2002;43:183–194
  35. Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci. 1995;761:311–335
  36. Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception. 1996;54:243–251
  37. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progesterone. Contraception. 2000;62:29–38
  38. Losert W, Casals-Stenzel J, Buse M. Progestogens with antimineralocorticoid activity. Arzneimittelforschung. 1985;35:459–471
  39. Pollow K, Juchem M, Elger W, Jacobi N, Hoffmann G, Mobus V. Dihydrospirorenone (ZK30595): a novel synthetic progesterone—characterization of binding to different receptor proteins. Contraception. 1992;46:561–574
  40. Rübig A. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Climacteric. 2003;6(Suppl. 3):49–55
  41. Schurmann R, Holler T, Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric. 2004;7:189–196
  42. Warming L, Ravn P, Nielsen T, Christiansen C. Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis. Climacteric. 2004;7:103–111
  43. Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause. 2005;12:716–727
  44. Oelkers W. Drospirenone, a progesterone with antimineralocorticoid properties: a short review. Mol Cell Endocrinol. 2004;217:255–261
  45. Elger W, Beier S, Pollow K, Garfield R, Shi SQ, Hillisch A. Conception and pharmacodynamic profile of drospirenone. Steroids. 2003;68:891–905
  46. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005;8(Suppl. 1):3–63
  47. Sitruk-Ware R. New progestogens. A review of their effects in perimenopausal and postmenopausal women. Drugs Aging. 2004;21:865–883
  48. Stanczyk FZ. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev Endocr Metab Disord. 2002;3:211–224
  49. World Health Report 2002. Reducing risks, promoting healthy life. Geneva, Switzerland: World Health Organization; 2002. Available at http://www.who.int/whr/2002/en/index.html [Accessed 6 July 2006].
  50. Kannel WB. Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertens. 2000;14:83–90
  51. Franklin SS, Gustin W, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997;96:308–315
  52. WHO Statistical Information System (WHOSIS). World health statistics 2006. Available at http://www.who.int/whosis/whostat2006/en/index.html [Accessed 6 July 2006].
  53. Mueck AO, Seeger H. Effect of hormone therapy on BP in normotensive and hypertensive postmenopausal women. Maturitas. 2004;49:189–203
  54. Preston RA, Alonso A, Panzitta D, et al. Additive effect of drospirenone/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril. Am J Hypertens. 2002;15:816–822
  55. Preston RA, White WB, Pitt B, et al. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens. 2005;18:797–804
  56. White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17β-estradiol, a novel hormone treatment in postmenopausal women with stage I hypertension. Circulation. 2005;112:1979–1984
  57. Mancia G, Omboni S, Parati G, Ravogli A, Villani A, Zanchetti A. Lack of placebo effect on ambulatory blood pressure. Am J Hypertens. 1995;8:311–315
  58. Staessen JA, Wang J-G, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1305–1315
  59. MacMahon S. Blood pressure and the prevention of stroke. J Hypertens Suppl. 1996;14:S39–S46
  60. Neal B, MacMahon S, Chapman N Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 2000;356:1955–1964
  61. Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913
  62. Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab. 1995;80:1816–1821
  63. Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care. 2000;5:124–134
  64. Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care. 2000;5:25–34

PII: S0378-5122(06)00282-9

doi: 10.1016/j.maturitas.2006.07.009

Maturitas
Volume 55, Issue 4 , Pages 297-307 , 20 November 2006

Article Tools

* Image Usage & Resolution